The Paris Private Equity team advised the shareholders of Citoxlab on granting an exclusivity to Charles River Laboratories International, Inc. in consideration for a binding offer of €448 million in cash (or approximately $510 million) for the acquisition of Citoxlab. The proposed transaction is subject to labor consultations, regulatory requirements, and customary closing conditions. Upon completion of the labor consultations, Citoxlab’s shareholders are expected to enter into a definitive purchase agreement.
Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing.
For additional details on the acquisition, please read the press release.